Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will be participating in a fireside chat at the JMP Securities Hematology and Oncology Summit.
JMP Securities Hematology and Oncology Summit
Date: Monday, December 6, 2021
Time: 12:40 PM ET
A live webcast of the fireside chat will be available via the Investors section of the Company's website at www.vorbio.com. An archived replay of the webcast will also be available following the conference.
About Vor Biopharma
Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contacts:
Investors:
Chris Brinzey
ICR Westwicke
+1 339-970-2843
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Sarah Spencer
Vice President, Corporate Communications, Vor
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.65 |
| Daily Volume: | 122,512 |
| Market Cap: | US$80.950M |
March 20, 2025 January 08, 2025 December 27, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
